Expect significant new tariffs on Chinese imports and moderate levies on goods from other nations , as President-elect Donald Trump rolls out his protectionist agenda. However, with his preference for chaotic policymaking and sudden shifts , there’s uncertainty on how soon these import taxes will actually hit. Dubbed “ Tariff Man ,” Trump aims to use tariffs both strategically and tactically . He’s mentioned taxing all Chinese goods up to 60% and potentially setting 10%-20% tariffs on imports globally , but details on these plans remain vague . Key players within Trump’s team are divided: Robert Lighthizer , a staunch tariff advocate, sees permanent duties as crucial to balance US trade , while others, like billionaires John Paulson and Scott Bessent , view tariffs as temporary leverage. Trump’s previous administration had mixed feelings, especially on national security-related trade limits , which he sometimes dismissed, favoring an “open for business” approach. High-profile busin
CIMB Securities, one of the few research houses covering Genetec, issued a warning on Friday about a potential 30% decline in the company’s earnings for the fiscal year ending June 30, 2025 (FY2025). This projection stems from delays in securing new orders from a key automotive manufacturer that has adopted a more cautious approach to capacity expansion.
As a result, CIMB Securities downgraded Genetec's stock from 'buy' to 'hold' and significantly lowered its target price from RM3.70 to RM1.60. The firm cited concerns over Genetec’s business outlook, highlighting uncertainties ahead of the U.S. presidential election and a moderating growth outlook in the global electric vehicle (EV) market as key factors.
Market speculation points to Tesla’s order deferments as a significant reason for this downgrade. There are also concerns that Genetec’s upcoming quarterly results, expected by the end of this month, could fall below consensus estimates.
Genetec is largely owned by institutional investors, with the Employees Provident Fund holding the largest stake at 9.33%. Other significant institutional shareholders include Principal Global Investors LLC, Hong Leong Asset Management Bhd, and Norges Bank Investment Management. Notably, Genetec's co-founder Aaron Chen Khai Voon reduced his stake in the company by 2.25% between May and July, bringing his ownership down to 7.39%.
The cautious stance taken by CIMB Securities reflects broader market concerns, as Genetec's shares have experienced significant sell-offs, recently plunging to their lowest level since July 2021.
Comments
Post a Comment